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Summary  We  herein  describe  the  nosocomial  transmission  of  a  pre-XDR  or  MDR
case  of  pulmonary  tuberculosis  in  a  HIV-negative  health  care  worker  in  an  area
endemic  for  MDR  and  XDR  tuberculosis.  Following  inadequate  therapy  and  non-
compliance,  he  presented  with  extra-pulmonary  XDR  tuberculosis  in  the  form  of
multi-focal  osteomyelitis  and  encysted  pleural  effusion.  He  was  cured  after  two
years  of  treatment  with  various  anti-tuberculous  drugs  in  addition  to  interferon
gamma.
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hase presentation
he  case  was  a  30-year-old  Saudi  physician  who
tudied  medicine  for  six  years  in  the  Ukraine  from
992  until  1997.  He  denied  direct  contact  with
atients  who  had  extensively  drug-resistant  tuber-
ulosis.  He  described  having  indirect  contact  with
hese patients  in  January  2006.  These  patients  were
aiting in  the  radiology  department  for  chest  X-
ays. In August  1996,  he  developed  a  fever  and
ough that  did  not  respond  to  one  week  of treat-
ent with  moxiﬂoxacin.  His  CT  chest  revealed  a
ight apical  cavity.  He  was  admitted  to  a  hospital
n Riyadh  and  was  started  on  isoniazid,  rifampin,
thambutol and  pyrizinamide  for  smear-positive
uberculous  cavitary  pulmonary  disease.  He  did  not
mprove  after  one  month  of  therapy.  Moxiﬂoxacin,
mikacin and  cycloserine  were  therefore  added.
is sputum  Mycobacterium  tuberculosis  [isolate
] was  sensitive  to  ethambutol  and  resistant  to
soniazid,  rifampin  and  streptomycin.  Second-line
rug susceptibility  information  was  not  available
Table  1).  He  improved  clinically  but  his  sputum
ultures continued  to  be  positive  for  M.  tubercu-
osis in  September  and  October  2006.  He  returned
Table  1  Tuberculosis  drug  susceptibilities  for  the
three  isolates  sputum  and  bone  (R:  resistant,  S:  sen-
sitive,  NP:  not  performed).
Tuberculosis  drug
sensitivities
Isolate  A
sputum
Isolate  B
sputum
Isolate  C
bone
Rifampin  R  R  R
Isoniazid  R  R  R
Pyrizinamide  R  R  R
Ethambutol  S  R  R
Streptomycin  R  R  R
Amikacin  NP  R  R
Capreomycin  NP  R  R
Kanamycin  NP  NP  R
Ethionamide  NP  R  R
Oﬂoxacin  NP  R  R
Moxiﬂoxacin  NP  NP  R
Linezolid  NP  S  S
PAS  NP  NP  R
Cycloserine  NP  S  NP
Clarithromycin  NP  NP  NP
Clofazimine  NP  S  NP
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to  the  Ukraine  in  November  2006  and  continued
n isoniazid,  rifampin,  ethambutol,  pyrizinamide,
oxiﬂoxacin and  cycloserine  for  six  months.  He
topped his  therapy  in  April  2007  and  developed
 recurrent  fever  and  cough  in  May  2007.  He
raduated in  July  2007  and  returned  to  Saudi
rabia to  be  admitted  for  pleura-pulmonary  tuber-
ulosis. His  sputum  was  smear-positive  and  his
leural  effusion  was  also  positive  for  M.  tuber-
ulosis. His  tuberculous  empyema  required  chest
ube drainage.  He  was  re-started  on  isoniazid,
ifampin, pyrizinamide,  ethambutol,  moxiﬂoxacin,
ycloserine and  amikacin.  In  July  2007,  second-
ine drug  susceptibility  testing  was  performed
y the  National  Tuberculosis  Reference  Labora-
ory, London,  UK.  His  sputum  M.  tuberculosis
isolate B]  was  resistant  to  isoniazid  (high  level
esistance),  rifampin,  ethambutol,  pyrazinamide,
ﬂoxacin, streptomycin,  amikacin,  capreomycin
nd ethionamide.  It  was  only  sensitive  to  line-
olid, clofazimine  and  cycloserine  (Table  1). He
ad no  medical  follow-up  from  September  2007
ntil July  2008.  He  sought  a  second  opinion  in  Jor-
an. He  felt  better  on  alternative  medicine  and  his
espiratory  symptoms  improved.  He  was  receiving
oxiﬂoxacin,  ethambutol  and  cycloserine  in  August
008 when  he  experienced  left  ankle  pain,  swelling
nd limitation  of  movement.  MRI  conﬁrmed  left
nkle osteomyelitis  (Fig.  1) and  he  underwent
ebridement.  Bone  histopathology  showed  caseat-
ng granuloma  with  negative  acid-fast  bacilli.  A
issue sample  from  the  ankle  bone  was  emulsiﬁed
n sterile  normal  saline  using  a  sterile  mortar  and
istol. Both  samples  were  inoculated  in  BACTEC-
GIT TB  liquid  culture  tubes  (BD  Biosciences,
parks, MD)  and  incubated  in  the  BACTEC-MEGIT
60 instrument  (BD  Biosciences)  until  there  was
ositive  detection  by  the  machine.  The  isolate
as conﬁrmed  to  be  M.  tuberculosis  by  PCR  using
he gene  GeneXpert  MTB/RIF  (Cepheid,  Sunny-
ale, CA).  Sensitivity  testing  to  isoniazid,  rifampin,
thambutol  and  streptomycin  were  performed  on
 MEGIT  960  instrument  (BD  Biosciences)  according
o manufacturer’s  instructions.  The  drug  concen-
rations  were  as  follows:  isoniazid  0.4  mg/ml,
ifampin 1  mg/ml,  ethambutol  5  mg/ml  and  strep-
omycin  4.0  mg/ml.  The  organism  was  resistant
o all  ﬁrst-line  drugs.  The  sample  was  referred
410  A.N.  Alshukairi  et  al.
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started after  six  months  of  therapy  when  the
linezolid and  amikacin  were  stopped.  It  was  con-
tinued for  six  months  with  no  adverse  effects.
After two  years  of  therapy,  the  patient  is clinicallyFigure  1  The  ﬁrst  MRI  of  the  left  ankle  showing
osteomyelitis  of  the  left  ﬁbula.
to  the  National  Tuberculosis  Reference  Labora-
tory, London,  UK  for  second-line  sensitivity  testing.
The bone  tissue  M.  tuberculosis  strain  [isolate  C]
was resistant  to  isoniazid,  rifampin,  pyrizinamide,
ethambutol, streptomycin,  amikacin,  capreomycin,
kanamycin, ethionamide,  para-aminosalicylic  acid
(PAS), oﬂoxacin  and  moxiﬂoxacin.  It  was  only  sen-
sitive to  linezolid.  The  sensitivity  to  cycloserine,
clofazimine and  clarithromycin  was  not  exam-
ined (Table  1).  Within  two  weeks,  the  patient
developed left  elbow  and  knee  pain,  swelling
and limitation  of  movement,  which  were  con-
ﬁrmed by  MRI  as  left  elbow  and  knee  osteomyelitis
(Figs.  2  and  3).  His  chest  CT  showed  right  encysted
pleural effusion  with  no  cavitary  pulmonary  dis-
ease. At  this  stage,  it  was  realized  that  this  patient
had serious  XDR  tuberculosis  in  the  form  of  multi-
focal osteomyelitis  and  encysted  pleural  effusion.
We used  a  combination  of  clofazimine,  linezolid,
meropenem, ampicillin-clavulanate,  cycloserine,
PAS, capreomycin  daily,  moxiﬂoxacin  and  clar-
ithromycin  for  two  months.  Subsequently,  he
was continued  on  PAS,  cycloserine,  moxiﬂoxacin,
azithromycin,  clofazimine,  linezolid  and  amikacin
every  other  day  (the  capreomycin  was  stopped)  for
four months.  Finally,  he  received  PAS,  cycloserine,
moxiﬂoxacin, clofazimine  and  azithromycin  for  18
months. He  developed  intolerable  gastro-intestinal
upset related  to  clarithromycin,  meropenem  and
ampicillin-clavulanate  and  they  were  stopped  after
two months  of  treatment.  He  developed  linezolid-
associated axonal  neuropathy  conﬁrmed  by  nerve
conduction  studies,  so  the  linezolid  was  stopped
after six  months  of  therapy.  Capreomycin  was
F
oigure  2  The  ﬁrst  MRI  of  the  left  elbow  showing
steomyelitis  of  the  left  humerus.
topped  after  two  months  because  it  was  not
vailable. He  was  continued  on  amikacin  for  four
onths  only  in  view  of  its  ototoxicity.  In  summary,
e received  a total  of  six  months  of  second-
ine injectable  agents.  Pyrizinamide  was  not  given
ecause of  the  patient’s  severe  polyarthritis.
ubcutaneous  interferon  gamma  injections  wereigure  3  The  ﬁrst  MRI  of  the  left  knee  showing
steomyelitis  of  the  left  femur.
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Figure  4  A  follow-up  MRI  of  the  left  ankle  after
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Figure  5  A  follow-up  MRI  of  the  left  elbow  after
12  months  of  treatment  showing  improvement  of  the
osteomyelitis  in  the  left  humerus.
Figure  6  A  follow-up  MRI  of  the  left  knee  after
1
o
d
i
o
o
f2  months  of  treatment  showing  improvement  of  the
steomyelitis  in  the  left  ﬁbula.
symptomatic  with  no  residual  joint  pain,  swelling
r limitation  of  movement.  His  HIV  serology  is
egative.  His  CRP  and  ESR,  as  well  as  his  com-
lete blood  count  and  renal  and  liver  function
ests are  normal.  After  one  year  of  therapy,
 follow-up  MRI  of  his  left  ankle,  elbow  and
nee showed  80%  improvement  of  the  osteomyeli-
is (Figs.  4—6)  and  his  CT  chest  revealed  50%
esolution of  his  encysted  pleural  effusion.  After
8 months  of  therapy,  his  left  knee  MRI  showed
esolution of  the  osteomyelitis  (Fig.  7).  He  has
een asymptomatic  since  the  discontinuation  of  his
nti-tuberculous  medication  in  March  2011.  As  he
s doing  postgraduate  studies  outside  Saudi  Ara-
ia at  this  time,  follow-up  imaging  could  not  be
erformed.
ase discussion
ur  case  illustrates  the  nosocomial  transmission  of
DR tuberculosis  to  a  health  care  worker  in  an  area
ndemic  for  resistant  tuberculosis.  The  nosocomial
ransmission of  MDR  tuberculosis  is  a  real  concern
n resource-poor  settings.  It  has  been  estimated
hat the  application  of  nosocomial  infection  control
trategies  could  prevent  half  of  XDR  tuberculosis
ases [1].
It was  difﬁcult  to  determine  whether  our  caseas initially  an  MDR  tuberculosis  stain  or  an  XDR
tain due  to  the  lack  of  second-line  drug  sus-
eptibility testing  on  specimen  A.  However,  the
n
t
p2  months  of  treatment  showing  improvement  of  the
steomyelitis  in  the  left  femur.
evelopment  of  secondary  ethambutol  resistance
n specimen  B is  an  indicator  of  the  propagation
f resistance.  Our  case  demonstrates  the  vari-
us risk  factors  for  the  progression  of tuberculosis
rom MDR  to  XDR  strains.  First,  our  patient  was
on-compliant with  his  therapy  and  did  not  con-
inue his  medical  follow-up.  In  MDR  tuberculosis
atients with  baseline  resistance  to  second-line
412  
Figure  7  A  follow-up  MRI  of  the  left  knee  showing  res-
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In our  case,  with  the  limited  options  availableolution  of  the  osteomyelitis  in  the  left  femur  after  18
months  of  therapy.
drugs,  it  was  shown  that  the  risk  of  XDR  tuber-
culosis increased  from  1.4%  to  15.9%  in  directly
observed therapy  programs,  whereas  it  increased
from 3.4%  to  60.9%  in  indirectly  observed  ther-
apy programs  [2]. Second,  our  case  illustrates  that
the presence  of  cavitary  pulmonary  disease  is  an
important  risk  factor  for  the  ampliﬁcation  of  sec-
ondary resistance  among  MDR  and  XDR  tuberculous
bacilli. It  was  previously  found  that  25%  of  resected
pulmonary cavity  XDR  tuberculosis  cases  had  addi-
tional drug  resistance  compared  to  preoperative
sputum tuberculous  cultures  [3].  Third,  the  extent
of resistance  to  second-line  drugs  was  initially
unknown in  our  MDR  tuberculosis  case,  leading
to inadequate  therapy  and  a  complicated  out-
come. It  was  shown  that  2.4%  of  MDR  tuberculosis
patients with  no  baseline  second-line  drug  resis-
tance developed  acquired  XDR  tuberculosis,  while
44.1% of  those  with  resistance  to  three  second-
line drugs  developed  acquired  XDR  tuberculosis
[2].
The  resistance  of  our  case  was  conﬁrmed  by
direct susceptibility  testing  of  sputum  and  bone
tuberculous  cultures.  The  diagnosis  of  XDR  tuber-
culosis  osteomyelitis  is  challenging.  The  disease
is paucibacillary  and  requires  invasive  procedures.
The genotype  line  probe  assays  for  rifampin,
second-line  injectable  agents  and  ﬂuoroquinolones
are promising  in  respiratory  specimens  but  require
further  evaluation  in  non-respiratory  specimens
[4].  Because  they  are  dependent  on  the  gold
f
i
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tandard,  slow,  direct  susceptibility  testing,  the
iagnosis and  initiation  of  effective  therapy  are
elayed for  several  weeks  in  cases  of  XDR
uberculosis osteomyelitis.  In  addition,  follow-up
pecimens to  assess  the  disease  response  were  lack-
ng in  our  case,  although  we  clearly  demonstrated
he radiological  improvement  of  osteomyelitis  after
dequate therapy  in  addition  to  the  patient’s  clini-
al response.
The  optimal  treatment  for  MDR  and  XDR  extra-
ulmonary tuberculosis  is  difﬁcult  to  determine  and
as not  been  clearly  demonstrated.  The  guidelines
or the  management  of MDR  and  XDR  extra-
ulmonary tuberculosis  were  adopted  from  the
reatment  guidelines  for  MDR  and  XDR  pulmonary
uberculosis. The  WHO  guidelines  for  XDR  tuber-
ulosis therapy  suggested  six  medications  in  the
nduction  phase  for  eight  months  and  four  med-
cations in  the  maintenance  phase  for  12  months
5].
In our  case,  we  could  not  adopt  the  WHO  guide-
ines. The  treatment  was  challenging  for  several
easons. First,  the  strain  was  only  sensitive  to  line-
olid and  clofazimine  and  might  have  been  sensitive
o cycloserine  (the  patient  was  previously  exposed
o cycloserine).  Second,  the  patient  had  an  inter-
upted  exposure  to  cycloserine,  moxiﬂoxacin  and
mikacin,  which  made  it  more  difﬁcult  to  build  an
ffective drug  regimen  for  him.  Third,  several  med-
cations  were  not  available  in  Saudi  Arabia,  such
s PAS  and  capreomycin,  and  were  purchased  using
ersonnel  efforts  and  communications.  Fourth,
he best  drug  combination  to  provide  effective
one penetration  is  not  known.  Fifth,  the  treat-
ent plan  was  modiﬁed  because  of  drug  toxicity
nd intolerance  (pyrizinamide,  linezolid,  amikacin,
larithromycin,  clavulanate  and  meropenem).  We
iscussed our  case  with  several  international  XDR
uberculosis  experts  and  we  agreed  that  the  ther-
py should  be  tailored  for  the  above  reasons.  The
ifﬁculty  in  building  our  regimen  relied  on  combin-
ng medications  with  limited  beneﬁt  to  which  the
atient had  not  been  exposed  (meropenem,  clavu-
anate, clarithromycin,  clofazimine  and  linezolid)
nd adding  medications  with  proven  beneﬁt  but
ith known  resistance,  to  which  the  patient  was
xposed  (cycloserine,  moxiﬂoxacin  and  amikacin).
he induction  phase  was  shortened  to  six  months
n view  of  drug  toxicity  (linezolid  and  amikacin)
nd drug  intolerance  (meropenem,  clavulanate,
nd clarithromycin)  with  a sequential  reduction  of
edication  from  nine  drugs  to  ﬁve  drugs.or sensitive  drugs,  resistant  drugs  such  as  mox-
ﬂoxacin,  PAS,  amikacin  and  capreomycin  were
sed. Despite  the  bacteria  being  resistant,  the
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Ruccessful  treatment  of  multi-focal  XDR  tuberculou
se  of  moxiﬂoxacin  is  recommended  in  XDR  tuber-
ulosis  to  improve  the  treatment  outcome  [5,6].
t is  not  known  whether  the  use  of  other  resis-
ant medications,  such  as  second-line  injectable
rugs, will  lead  to  a  similar  outcome.  The  syner-
istic effects  of  resistant  anti-tuberculous  agents
re unknown  and  need  to  be  evaluated.  In  addi-
ion,  with  the  availability  of  new  drugs  for  resistant
uberculosis,  the  best  combination  therapy  with
he lowest  pill  burden  and  shortest  effective  ther-
py needs  to  be  determined  in  future  studies.  In
he French  cohort  study  that  evaluated  the  efﬁ-
acy of  bedaquiline,  19  out  of  35  patients  had  XDR
uberculosis  and  one  case  was  osteoarticular  tuber-
ulosis.  After  six  months  of  therapy,  all  but  one  of
he patients  had  culture  conversion.  This  cohort
tudy also  showed  that  bedaquiline  had  a  favor-
ble outcome  when  combined  with  moxiﬂoxacin,
ven though  the  tuberculous  strains  were  resistant
o ﬂuoroquinolones  [7].
The role  of  immune  modulation  and  the  use  of
nterferon gamma  in  XDR  tuberculosis  are  contro-
ersial  and  poorly  studied  [8].  We  used  interferon
amma injections  in  our  case  when  our  patient
eveloped adverse  effects  related  to  linezolid  and
mikacin  and  the  number  of  drugs  in  the  induc-
ion phase  was  reduced.  Further  clinical  studies  are
eeded to  evaluate  its  efﬁcacy  against  XDR  tubercu-
osis. At  present  it  may  be  considered  in  refractory
ases of  XDR  tuberculosis  despite  optimal  ther-
py and  in  the  presence  of  medication-related  side
ffects.
Our case  is unique  in  the  literature  in  that  it  is
 case  of  multifocal  XDR  tuberculous  osteomyelitis
ith a  successful  outcome.  The  literature  describ-
ng MDR  and  XDR  tuberculous  osteomyelitis  is
imited  to  a  few  case  reports  [9—12].  All  of  the  pre-
ious cases  reviewed  were  MDR  tuberculosis  and  not
DR tuberculosis.  A  systematic  review  summarized
3 case  reports,  and  indicated  that  six  patients
ad spinal  disease  and  seven  patients  had  extra-
pinal  disease.  All  of  them  had  a  good  outcome  with
edical  therapy.  Eight  of  them  required  surgical
ntervention [11].
onclusion
he  diagnosis  and  management  of  extra-pulmonary
DR tuberculosis  remains  challenging,  particularly
ecause it  is endemic  in  resource-limited  countries.
ith  the  lack  of  rapid  diagnostics  and  effectiveherapy, preventive  strategies  are  crucial.  Reli-
ble molecular  testing  and  low-burden  treatments
re areas  that  should  be  addressed  in  future
esearch.teomyelitis  413
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